Read More

Dario Launches Agreement With Large Regional Health Plan And Announces Preliminary Results For Q2 2023 As Well As Business Update; Sees Q2 Revenue $6M-$6.15M Vs $6.73M Est.; Preliminary Unaudited Cash And Cash Equivalents Of $52.6M As Of June 30

New account is set to launch in July 2023 for eligible members NEW YORK, July 24, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in

DRIO

Read More

Janssen To Discontinue Internal Development Of Cidara Therapeutics-Partnered Influenza Candidate

Cidara Therapeutics Inc (NASDAQ: CDTX) provided an update on the status of its ongoing CD388 program for the prevention of influenza A and B under an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc, a part of Johnson & John

CDTX